Company intelligence / Profile preview

Predicant Biosciences

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Predicant Biosciences was a biotechnology company focused on the discovery and development of protein-based diagnostic tests. The company utilized a proprietary mass spectrometry-based platform to identify patterns of proteins in blood that could indicate the presence of disease or monitor treatment response. By combining advanced analytical chemistry with sophisticated bioinformatics, Predicant aimed to provide clinicians with high-resolution molecular information for personalized medicine. The company was acquired by Becton, Dickinson and Company (BD) in 2006 to bolster BD's proteomics and diagnostic capabilities.

Therapeutic areas: OncologyImmunology
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Predicant Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Predicant Biosciences.

Explore the full profile